Windlas Biotech (NSE:WINDLAS) Total Liabilities: ₹3,265 Mil (As of Mar. 2026)


NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
89 GF Score
Price ₹871.90
GF Value ₹934.52
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Total Liabilities?

Windlas Biotech NSE:WINDLAS +1.24% 89 Total Liabilities is ₹3,265 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹934.52 (Fairly Valued). The stock has 1 warning sign investors should review.

Windlas Biotech's Total Liabilities for the quarter that ended in Mar. 2026 was ₹3,265 Mil.

Windlas Biotech's quarterly Total Liabilities declined from Sep. 2025 (₹2,801.16 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹3,265.10 Mil).

Windlas Biotech's annual Total Liabilities increased from Mar. 2024 (₹1,762.70 Mil) to Mar. 2025 (₹2,546.78 Mil) and increased from Mar. 2025 (₹2,546.78 Mil) to Mar. 2026 (₹3,265.10 Mil).

Windlas Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Total Liabilities Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial 962.34 1,267.04 1,762.70 2,546.78 3,265.10

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,546.78 0.00 2,801.16 0.00 3,265.10
NSE:WINDLAS
89GF Score
Windlas Biotech Ltd NSE:WINDLAS
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Windlas Biotech's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3209.3+(21.48+0.99999999999972
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+33.32+0)
=3,265

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=9073.48-5808.38
=3,265

Windlas Biotech's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=3209.3+(21.48+0.99999999999972
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+33.32+0)
=3,265

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=9073.48-5808.38
=3,265

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹3,265 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Total Liabilities of ₹3,265 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Windlas Biotech and its competitors.
Is Windlas Biotech's Total Liabilities too high?
Windlas Biotech's current Total Liabilities is ₹3,265 Mil. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Total Liabilities compare to ZTS and UTHR?
Windlas Biotech's Total Liabilities of ₹3,265 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Windlas Biotech and its competitors. Windlas Biotech's current Total Liabilities is ₹3,265 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹934.52, compared to a current price of ₹871.90 — trading 6.7% below its estimated fair value. The current Total Liabilities is ₹3,265 Mil. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Total Liabilities is ₹3,265 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹871.90 is trading 6.7% below its estimated GF Value™ of ₹934.52. GuruFocus considers Windlas Biotech to be Fairly Valued.

Key valuation signals for NSE:WINDLAS:

  • Total Liabilities: ₹3,265 Mil
  • GF Value™: ₹934.52 vs. price of ₹871.90 (6.7% below fair value)
  • GF Score™: 89/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score

Get the complete analysis for NSE:WINDLAS

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹871.90
Price
₹934.52
GF Value